Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absence, accrual, anemia, antibody, Arch, arm, autoreactive, cancer, celiac, destroying, diagnosed, diet, enriched, Fasano, fatigue, free, Gastroenterology, gluten, Herold, Immunol, intestine, itchy, landmark, Malamut, malnourishment, marker, mechanism, mechanistic, Med, MHC, monoclonal, moved, Nat, nausea, NHP, Northern, overruled, pancreatic, pharmacodynamic, PMID, prejudice, primate, proliferation, Rev, Standstill, stimulated, Stipulation, treating, Treg, unstimulated, upregulate, vehicle, volunteer, week
Removed:
AA, amalgamation, asserted, entitle, franchise, interfere, molecule, shareholder, unchanged, void
Filing tables
Filing exhibits
FBRX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Forte Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: August 14, 2024 | By: |
| /s/ Antony Riley |
|
|
| Antony Riley |
|
|
| Chief Financial Officer |